cx-546 cx-546 cx-546 is an ampakine drug developed by cortex pharmaceuticals. cx-546clinical dataother namescx-546legal statuslegal status us: investigational new drug identifiers iupac name 2,3-dihydro-1,4-benzodioxin-7-yl-(1-piperidyl)methanone cas number215923-54-9 ypubchem cid2890iuphar/bps4166chemspider2787 nuniipv6yec8983comptox dashboard (epa)dtxsid70175951 chemical and physical dataformulac14h17no3molar mass247.294 g·mol−13d model (jsmol)interactive image smiles c1ccn(cc1)c(=o)c2=cc3=c(c=c2)occo3 inchi inchi=1s/c14h17no3/c16-14(15-6-2-1-3-7-15)11-4-5-12-13(10-11)18-9-8-17-12/h4-5,10h,1-3,6-9h2 nkey:ljunphmognffos-uhfffaoysa-n n ny (what is this?) (verify) it has been proposed as a treatment for schizophrenia. cx-546 was the second drug of note to come out of the cortex research program, after cx-516, but while it was an improvement over its predecessor in some respects, it still has problems with limited oral bioavailability. however, cx-546 still represented a significant advance that led on to the development of newer compounds such as cx-614 and cx-717 with superior properties over the earlier drugs. cx-546 itself has been investigated for other applications, and most notably has been found to show significant efficacy in reversing the respiratory depression produced by sedative drugs such as opioids and barbiturates. no effective respiratory stimulants are currently marketed for this application, with cx-546 being only the third drug discovered (after bimu-8 and bw373u86) that effectively relieves the respiratory depression induced by fentanyl without reducing the analgesic effects. cx-546 could be developed for this purpose, although it is more likely that cortex will use newer and more potent analogues such as cx-1739 or cx-1763, which are likely to be more suitable for commercial development.